N-<2-(1H-imidazol-1-yl)phenyl>acetamide | 68030-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-<2-(1H-imidazol-1-yl)phenyl>acetamide
• 英文别名: N-(2-(1H-imidazol-1-yl)phenyl)acetamide；N-(2-1H-imidazol-1-ylphenyl)acetamide；N-(2-imidazol-1-yl-phenyl)-acetamide；1-(2-acetamidophenyl)imidazole；N-(2-imidazol-1-ylphenyl)acetamide
• CAS: 68030-24-0
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: RRODTPMBZSDNTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-<2-(1H-imidazol-1-yl)phenyl>acetamide 生成 4-甲基咪唑并[1,2-a]喹喔啉
  参考文献：
  名称：

  BAPHEP, P. L.;LUBER, EH. DZH.

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(2-硝基苯基)-1H-咪唑 在 硫酸 、 溶剂黄146 、 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 16.5h， 生成 N-<2-(1H-imidazol-1-yl)phenyl>acetamide
  参考文献：
  名称：

  Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi’s Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

  摘要：

  The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.

  DOI：

  10.1021/acs.jmedchem.8b01827

文献信息

• N-Arylations of Nitrogen-Containing Heterocycles with Aryl and Heteroaryl Halides Using a Copper(I) Oxide Nanoparticle/1,10-Phenanthroline Catalytic System
  作者：Jin-Heng Li、Bo-Xiao Tang、Sheng-Mei Guo、Man-Bo Zhang

  DOI：10.1055/s-2008-1067014

  日期：2008.6

  and indoles, with aryl and heteroaryl halides catalyzed by copper(I) oxide (Cu 2 O) nanoparticles is demonstrated. Four types of Cu 2 O were evaluated: the bulky compound and its cubic, octahedral, and spherical nanoparticulate forms. The results show that Cu 2 O nanoparticles, in particular the cubic form, are highly efficient for the N-arylation reaction. In the presence of cubic Cu 2 O nanoparticles

  演示了含氮杂环（即咪唑、三唑和吲哚）的无溶剂 N-芳基化的一般程序，其中芳基和杂芳基卤化物由氧化铜 (I) (Cu 2 O) 纳米颗粒催化。评估了四种类型的 Cu 2 O：大体积化合物及其立方、八面体和球形纳米颗粒形式。结果表明，Cu 2 O 纳米颗粒，特别是立方形式，对 N-芳基化反应非常有效。在立方 Cu 2 O 纳米粒子、1,10-菲咯啉和四丁基氟化铵存在下，多种含氮杂环在 110-145 °C 下与芳基和杂芳基卤化物顺利进行 N-芳基化反应，得到相应的产物以优异的产量。值得注意的是，该反应是在无溶剂条件下进行的。
• Lampe, John W.; Meo, Susan V. Di; Traina, Joseph A., Journal of Heterocyclic Chemistry, 1994, vol. 31, # 2, p. 287 - 292
  作者：Lampe, John W.、Meo, Susan V. Di、Traina, Joseph A.

  DOI：——

  日期：——
• BAPHEP, P. L.;LUBER, EH. DZH.
  作者：BAPHEP, P. L.、LUBER, EH. DZH.

  DOI：——

  日期：——
• US4172947A
  申请人：——

  公开号：US4172947A

  公开（公告）日：1979-10-30
• Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi’s Sarcoma-Associated Herpesvirus/Human Herpesvirus 8
  作者：Philine Kirsch、Valentin Jakob、Kevin Oberhausen、Saskia C. Stein、Ivano Cucarro、Thomas F. Schulz、Martin Empting

  DOI：10.1021/acs.jmedchem.8b01827

  日期：2019.4.25

  The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.